TfR mAb-Cross-Linked Rituximab/MTX-PEG-PLL-PLGA Drug-Loaded Nanoparticles Enhance Anticancer Action in B Lymphocytes
In vitro cytotoxicity evaluation of SU-DHL-4 cells using CCK assay. The SU-DHL-4 cells were treated by different drugs for 48 hours. (a) PEG-PLL-PLGA, (b) Rituximab, (c) MTX, (d) Rituximab combined with MTX, and (e) TfR mAb/Rituximab/MTX-PEG-PLL-PLGA nanoparticles. Data are shown as the .;.
Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.